From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesEpidaza
CAS Number
PubChem CID
Chemical and physical data
Molar mass390.4 g/mol g·mol−1
3D model (JSmol)

Chidamide (Epidaza) is a histone deacetylase inhibitor (HDI) developed wholly in China.[1] It was also known as HBI-8000.[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.[3]

Chidamide is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and has orphan drug status in Japan.[2][better source needed] As of April 2015 it is only approved in China.[1]

Chidamide is being researched as a treatment for pancreatic cancer.[4][5][6] However, it is not US FDA approved for the treatment of pancreatic cancer.


  1. ^ a b "China's First Homegrown Pharma". April 2015.
  2. ^ a b 2
  3. ^ HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai. Feb 2016
  4. ^ Qiao, Z (2013-04-26). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochem Biophys Res Commun. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
  5. ^ Guha, Malini (2015-04-01). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews Drug Discovery. 14 (4): 225–226. doi:10.1038/nrd4583. PMID 25829268.
  6. ^ Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.